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Objectives: The efficacy and hepatic safety of the non-nucleoside reverse transcriptase inhibitors rilpivirine
(TMC278) and efavirenz were compared in treatment-naive, HIV-infected adults with concurrent hepatitis B
virus (HBV) and/or hepatitis C virus (HCV) infection in the pooled week 48 analysis of the Phase III, double-
blind, randomized ECHO (NCT00540449) and THRIVE (NCT00543725) trials.
Methods: Patients received 25 mg of rilpivirine once daily or 600 mg of efavirenz once daily, plus two
nucleoside/nucleotide reverse transcriptase inhibitors. At screening, patients had alanine aminotransferase/
aspartate aminotransferase levels ≤5× the upper limit of normal. HBV and HCV status was determined at base-
line by HBV surface antigen, HCV antibody and HCV RNA testing.
Results: HBV/HCV coinfection status was known for 670 patients in the rilpivirine group and 665 in the efavirenz
group. At baseline, 49 rilpivirine and 63 efavirenz patients [112/1335 (8.4%)] were coinfected with either HBV
[55/1357 (4.1%)] or HCV [57/1333 (4.3%)]. The safety analysis included all available data, including beyond
week 48. Eight patients seroconverted during the study (rilpivirine: five; efavirenz: three). A higher proportion
of patients achieved viral load ,50 copies/mL (intent to treat, time to loss of virological response) in the sub-
group without HBV/HCV coinfection (rilpivirine: 85.0%; efavirenz: 82.6%) than in the coinfected subgroup (rilpi-
virine: 73.5%; efavirenz: 79.4%) (rilpivirine, P¼0.04 and efavirenz, P¼0.49, Fisher’s exact test). The incidence of
hepatic adverse events (AEs) was low in both groups in the overall population (rilpivirine: 5.5% versus efavirenz:
6.6%) and was higher in HBV/HCV-coinfected patients than in those not coinfected (26.7% versus 4.1%,
respectively).
Conclusions: Hepatic AEs were more common and response rates lower in HBV/HCV-coinfected patients treated
with rilpivirine or efavirenz than in those who were not coinfected.
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Introduction
As HIV type-1 (HIV-1), hepatitis B virus (HBV) and hepatitis C virus
(HCV) share transmission routes, patients with HIV are frequently
coinfected with HBV or HCV. Approximately 2–4 million
HIV-infected people worldwide have chronic HBV and 4–5
million have chronic HCV coinfection.1 In Western Europe and
the USA, chronic HBV infection has been found in 6%–14%
and HCV infection in 25–30% of HIV-positive individuals.1
Data suggest that coinfection affects the overall survival of
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HIV-infected patients, with a 3.6- to 8-fold increased risk of liver-
related mortality in HIV/HBV-coinfected individuals.2,3 Further-
more, in both HCV- and HBV-infected patients, HIV coinfection
has been associated with more rapid progression of viral
hepatitis-related liver disease (e.g. cirrhosis, end-stage liver
disease, hepatocellular carcinoma and liver failure).3 – 5
Antiretroviral drugs (ARVs) that are active against HIV and
HBV, such as tenofovir, lamivudine and emtricitabine, can direct-
ly suppress HBV replication and thus prevent or slow the progres-
sion of liver disease.6 – 8 Although HCV replication is not inhibited
by antiretroviral treatment, HCV treatment outcomes can
improve as a result of suppressed HIV replication and increased
CD4 cell count.9 Based on these findings, current HIV therapy
guidelines recommend that HIV patients with HBV, and possibly
with HCV coinfection, begin highly active antiretroviral treatment
(HAART), regardless of their CD4 cell count.10 – 12
Several studies have shown that hepatotoxicity can occur
with any antiretroviral and the risk of severe toxicity following
initiation of HAART is higher in HBV- or HCV-coinfected indivi-
duals.13 – 20 Non-nucleoside reverse transcriptase inhibitors
(NNRTIs) have been associated with hepatotoxicity, both in
clinical trials and in practice.21 – 25 Liver-related adverse events
(AEs) occur less frequently with efavirenz than with nevirapine.
The frequency of severe elevations in liver transaminases
ranges from 1% to 8% in patients receiving efavirenz26 – 33
compared with from 4% to 18% in patients receiving nevira-
pine.23,29 – 34 In addition, nevirapine hepatotoxicity has been
more frequent in females and in individuals with higher CD4
cell counts at the initiation of HAART.25,35
The NNRTI rilpivirine (TMC278; EDURANTw) has recently been
approved for use in the USA, Canada and Europe in combination
with other ARVs in HIV-1-infected treatment-naive adult
patients.36 – 38 Rilpivirine has been compared with efavirenz, each
in combination with two nucleoside/nucleotide reverse transcript-
ase inhibitors [N(t)RTIs], in two Phase III, randomized, double-
blind, double-dummy trials [ECHO (TMC278-C209,
NCT00540449) and THRIVE (TMC278-C215, NCT00543725)] in
treatment-naive, HIV-1-infected adults. In the pooled week 48
primary analysis of the two trials, compared with efavirenz, rilpivir-
ine had non-inferior efficacy and a more favourable tolerability
profile, with lower overall incidences of treatment-related grade
2–4 AEs, rash and neuropsychiatric AEs, and smaller lipid
increases.39
Given that HIV patients coinfected with HBV and/or HCV have
a higher risk of developing hepatic-related AEs with NNRTIs,32,40
we analysed the efficacy and safety of rilpivirine compared with
efavirenz in this subgroup of patients, using pooled week 48
Phase III data from the ECHO and THRIVE trials.
Methods
Trial design
ECHO and THRIVE were two Phase III, double-blind, double-dummy,
international randomized trials in treatment-naive, HIV-1-infected
adults (NCT00540449 and NCT00543725, respectively; www.
clinicaltrials.gov). Their primary objective was to determine whether rilpi-
virine was non-inferior to efavirenz in overall response [confirmed viral
load ,50 copies/mL, intent to treat, time to loss of virological response
(ITT-TLOVR), 12% non-inferiority margin] at week 48. The trial design
and methods have been reported in detail for the individual trials.41,42
The main inclusion criteria were viral load ≥5000 copies/mL, absence
of NNRTI resistance-associated mutations (based on a list of 39 out of 44
known NNRTI mutations)41 – 43 and susceptibility to the N(t)RTIs in the
background regimen as determined by vircowTYPE HIV-1 (Virco, Beerse,
Belgium). Patients with clinically significant hepatic impairment or
alanine aminotransferase (ALT) and/or aspartate aminotransferase
(AST) levels that were five times above the upper limit of normal were
excluded from the trials. Patients diagnosed with acute clinical viral hepa-
titis during the trial were withdrawn. The HBV and HCV status was deter-
mined at baseline by HBV surface antigen, HCV antibody and HCV RNA
testing.
The patients were randomized 1:1 to receive 25 mg of rilpivirine once
daily or 600 mg of efavirenz once daily, plus a combination of two
N(t)RTIs: tenofovir/emtricitabine in the ECHO trial and investigator-
selected tenofovir/emtricitabine, zidovudine/lamivudine or abacavir/
lamivudine in the THRIVE trial.
Written informed consent was obtained from all participants. Trial
protocols were reviewed and approved by the appropriate institutional
Ethics Committees and Health Authorities, and the trials were conducted
in accordance with the Declaration of Helsinki.
AEs were assessed using the Clinical Trials Group’s ‘Division of AIDS
Table for Grading the Severity of Adult and Paediatric Adverse Events’
(version 1.0, December 2004).44 Reported AEs were classified using the
Medical Dictionary for Regulatory Activities (MedDRA version 11.0).45
Trial and subanalysis assessments
Efficacy and safety data were analysed according to HIV/HBV and/or HIV/
HCV coinfection status. The efficacy analysis included only patients with
HBV/HCV status available at baseline and data gathered up to week 48.
The safety analysis included all patients and all available data, including
those beyond week 48. The cut-off date for this analysis was 28 January
2010 for THRIVE and 1 February 2010 for ECHO. In addition, patients who
seroconverted for HBV/HCV during the trials were considered as HBV/HCV
coinfected in the safety analysis. Pharmacokinetic data were collected
and population-based pharmacokinetic parameters determined.
The ITT population was used for all efficacy analyses and all evalua-
tions were performed on pooled data from the two trials. Response
rate (defined as the proportion of patients with viral load ,50 copies/
mL) at week 48 was determined using the TLOVR algorithm. In
post-hoc analyses, Fisher’s exact test was used to compare differences
in the response rates between different subgroups and the Wilcoxon
signed-rank test was used for differences in the CD4 cell counts. The inci-
dences of hepatic AEs and laboratory abnormalities were assessed on all
available safety data from the trials. Fisher’s exact test (post-hoc ana-
lysis) was used to compare safety differences between the treatment
groups. The Wilcoxon rank-sum test (post-hoc analysis) was used to
compare population pharmacokinetic data.
Results
Baseline patient characteristics
A total of 1368 patients were randomized and treated in the two
trials (N¼686 in the rilpivirine group and N¼682 in the efavirenz
group; Figure 1). At baseline, the median viral load was 5.0 log10
copies/mL and the median CD4 cell count was 256 cells/mm3.
Demographics and baseline characteristics were well-balanced
between the treatment groups within each trial; the median
treatment duration was 56 weeks in both groups.39
At baseline, the HIV/HBV and/or HIV/HCV coinfection status
was determined in 1335 patients (N′¼670 in the rilpivirine
group and N′¼665 in the efavirenz group). A total of 8.4%
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(112/1335) of patients were coinfected with HBV and/or HCV:
7.3% (49/670) of patients in the rilpivirine group and 9.5%
(63/665) in the efavirenz group. HBV and HCV coinfection oc-
curred at similar frequencies, with 55/1357 patients (4.1%)
being HBV positive and 57/1333 patients (4.3%) being HCV
positive.
During the trial, an additional eight patients seroconverted for
HBV/HCV (five patients in the rilpivirine group and three in the
efavirenz group). Data from these patients were included in the
coinfected subgroup in the safety analysis.
Table 1 shows the baseline characteristics of patients with
known HIV/HBV and/or HIV/HCV coinfection status. The baseline
disease characteristics were suggestive of a slightly more
advanced HIV infection stage in patients in the rilpivirine-
coinfected group than in the other groups (Table 1).
Efficacy outcomes by treatment group at week 48
The response rate was greater overall in the subgroup of HIV
patients without HBV/HCV coinfection than in the subgroup of
Table 1. ECHO and THRIVE: baseline characteristics of patients according to HBV and/or HCV coinfection status at baseline (N¼1335)
Parameter
HIV patients with HBV/HCV coinfection HIV patients without HBV/HCV coinfection
25 mg of RPV once daily,
N¼49
600 mg of EFV once daily,
N¼63
25 mg of RPV once daily,
N¼621
600 mg of EFV once daily,
N¼602
Patient demographics
male, % 77.6 73.0 75.2 76.4
Caucasian/white, % 46.9 50.8 62.6 60.6
age (years), median (range) 38 (25–78) 35.5 (22–63) 36 (18–74) 36 (19–69)
Disease characteristics
HIV-1 viral load (log10 copies/mL),
median (range)
5.2 (3.2–6.2) 5.0 (3.2–6.1) 4.9 (2.2–7.3) 5.0 (3.0–6.7)
HIV-1 viral load .100000
copies/mL, %
61.2 47.6 44.8 51.8
CD4 count (cells/mm3), mean
(95% CI)
230 (198–263) 246 (216–276) 262 (251–273) 274 (262–285)
CDC category C, % 8.2 4.8 4.5 5.8
RPV, rilpivirine; EFV, efavirenz.
Randomly assigned 1:1 to RPV or EFV (N = 1368)
AE n = 23 (3.4%)
Other reason n = 2 (0.3%)
Randomly assigned to RPV (n = 686)
Received RPV (n = 686)
With HBV/HCV coinfection (n = 49)
Without HBV/HCV coinfection (n = 621)
Discontinued n = 94 (13.7%)
Reached virological endpoint n = 36 (5.2%)
Lost to follow-up n = 15 (2.2%)
Non-compliance n = 8 (1.2%)
Consent withdrawn n = 6 (0.9%)
Ineligibility to continue trial n = 2 (0.3%)
Sponsor’s decision n = 2 (0.3%)
Ongoing at week 48 n = 592 (86.3%)
Reasons for discontinuation:
Discontinued n = 112 (16.4%)
AE n = 53 (7.8%)
Reached virological endpoint n = 14 (2.1%)
Lost to follow-up n = 15 (2.2%)
Non-compliance n = 4 (0.6%)
Consent withdrawn n = 18 (2.6%)
Other reason n = 4 (0.6%)
Ineligibility to continue trial n = 2 (0.3%)
Sponsor’s decision n = 1 (0.1%)
criteria n = 1 (0.1%)
Failure to fulfil inclusion/exclusion
Reasons for discontinuation:
Ongoing at week 48 n = 570 (83.6%)
With HBV/HCV coinfection (n = 63)
Without HBV/HCV coinfection (n = 602)
Randomly assigned to EFV (n = 682)
Received EFV (n = 682)
Figure 1. CONSORT diagram showing patient disposition for the pooled primary analysis of ECHO and THRIVE. RPV, rilpivirine; EFV, efavirenz.
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HIV/HBV- and/or HIV/HCV-coinfected patients (P¼0.06; Fisher’s
exact test) (Table 2). Among patients with HIV/HBV and/or HIV/
HCV coinfection, 73.5% and 79.4% of patients in the
rilpivirine and efavirenz groups, respectively, achieved viral load
,50 copies/mL, whereas in non-coinfected patients the response
rates were 85.0% and 82.6%, respectively (Table 2). This difference
between coinfected and non-coinfected patients was significant
for rilpivirine (P¼0.04), though not for efavirenz (P¼0.49,
Fisher’s exact test).
Similarly, for rilpivirine the mean improvement in the CD4 cell
count was higher in the subgroup of HIV patients without coinfec-
tion than in the subgroup of patients with HBV/HCV coinfection
(Table 2). In patients with coinfection, the mean increase in the ab-
solute CD4 cell count from baseline was lower in the rilpivirine
group than in the efavirenz group (although the 95% confidence
intervals overlapped), while in non-coinfected patients the mean
increase was higher in the rilpivirine group (with no overlap in
the confidence intervals, Table 2). The change from baseline in
the CD4 cell count was statistically significant for each of the
four subgroups (P,0.0001; Wilcoxon signed-rank test).
HBV or HCV coinfection did not significantly influence rilpivirine
or efavirenz pharmacokinetics, with no effect on the area under
the concentration–time curve (AUC24) of rilpivirine or efavirenz
compared with non-coinfected patients (rilpivirine, P¼0.45; efa-
virenz, P¼0.71; Wilcoxon rank-sum test).
Hepatic safety and tolerability by treatment group
in the overall patient population
The overall incidence of hepatic AEs was low [5.5% (38/686) for
rilpivirine versus 6.6% (45/682) for efavirenz]. Hepatic AEs consid-
ered at least possibly related to treatment by the investigator
(treatment-related AEs) occurred in 2.2% (15/686) of patients
in the rilpivirine group and 2.1% (14/682) of patients in the efa-
virenz group. Increased AST [rilpivirine: 2.3% (16/686) versus efa-
virenz: 2.8% (19/682)] and increased ALT [1.9% (13/686) versus
2.8% (19/682), respectively] were the most commonly reported
hepatic AEs (regardless of causality). All other hepatic AEs oc-
curred in ,1% of patients in each treatment group. Most
hepatic AEs were asymptomatic grade 1 or 2 increases in trans-
aminase levels.
Serious hepatic AEs (regardless of causality) occurred infre-
quently in both treatment groups [rilpivirine: 0.4% (3/686)
versus efavirenz: 0.7% (5/682)]. Two serious treatment-related
hepatic AEs occurred. Both were in the efavirenz group and led
to discontinuation: one was a grade 3 increase in both ALT and
AST, and one a grade 3 increase in ALT. Hepatic AEs infrequently
led to treatment discontinuation, with three patients stopping
treatment permanently in the rilpivirine group (0.4%) compared
with nine patients in the efavirenz group (1.3%). No fatal hepatic
AEs occurred.
Regarding treatment-emergent hepatic laboratory abnormal-
ities, there was a lower incidence of grade 2–4 ALT and AST
elevations in the rilpivirine group than in the efavirenz group
[ALT: 5.1% (35/685) for rilpivirine versus 9.9% (66/670) for efavir-
enz, P¼0.0009; AST: 4.8% (33/685) versus 9.0% (60/669),
respectively, P¼0.003; Fisher’s exact test]. The incidence of
grade 2–3 total hyperbilirubinaemia was higher in the rilpivirine
group [3.1% (21/685) versus 0.4% (3/670) for efavirenz,
P¼0.0003; Fisher’s exact test].
Hepatic AEs by HIV/HBV and/or HIV/HCV
coinfection status
Compared with patients without HBV/HCV coinfection, coinfected
patients developed more hepatic AEs and laboratory abnormal-
ities reported as AEs in both treatment groups (Table 3). These
were mostly increases in AST and ALT levels.
Of the two serious hepatic AEs that occurred in the overall
population and considered at least possibly related to treatment,
one was in a coinfected patient (grade 3 increase in ALT while re-
ceiving efavirenz) and led to discontinuation. The other (grade 3
increase in ALT and AST) was in a non-coinfected patient
receiving efavirenz.
Table 2. Pooled week 48 efficacy outcomes for patients with known HBV and/or HCV coinfection status at baseline (N¼1335)
Efficacy parameters at week 48a
HIV patients with HBV/HCV coinfection HIV patients without HBV/HCV coinfection
25 mg of RPV once
daily, N¼49
600 mg of EFV once
daily, N¼63
25 mg of RPV once
daily, N¼621
600 mg of EFV once
daily, N¼602
Patients with viral load ,50 copies/mL
(ITT-TLOVR), % (95% CI)
73.5 (61–86) 79.4 (69–90) 85.0 (82–88) 82.6 (80–86)
Virological failures, n (%) 5 (10.2) 3 (4.8) 55 (8.9) 30 (5.0)
Discontinuation due to AE/death, n (%) 2 (4.1) 6 (9.5) 13 (2.1) 40 (6.6)
Discontinuation due to reason other than
AEb, n (%)
6 (12.2) 4 (6.3) 25 (4.0) 35 (5.8)
Change in CD4 count (NC¼Fc) from
baseline (cells/mm3), mean (95% CI)d
+137 (100–175) +192 (147–238) +197 (186–209) +173 (161–185)
RPV, rilpivirine; EFV, efavirenz.
aPatients included in efficacy analysis were those with baseline HBV/HCV assessments.
bLost to follow-up, non-compliance, withdrew consent, ineligible to continue, sponsor’s decision.
cNC¼F, non-completer¼ failure: missing values after discontinuation imputed with change¼0; last observation carried forward otherwise.
dN′¼48 for rilpivirine for HBV- and/or HCV-coinfected patients.
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Three patients in the rilpivirine group discontinued for hepatic
AEs; two were HBV/HCV coinfected and one patient had an
unknown coinfection status. Of the nine patients in the efavirenz
group who discontinued for this reason, six were HBV/HCV coin-
fected and one patient had an unknown coinfection status.
The reason for discontinuation in the two HBV/HCV-coinfected
patients in the rilpivirine group was a grade 3 or 4 increase in
AST and/or ALT levels (as required by the protocol). One of the
six HBV/HCV-coinfected patients in the efavirenz group also dis-
continued for this reason and the other five discontinued for
HCV (n¼2), cytolytic HCV (n¼1), elevated hepatic enzymes
(n¼1) and abnormal hepatic function (n¼1).
Hepatic laboratory abnormalities by HIV/HBV
and/or HIV/HCV coinfection status
In both treatment groups, grade 2–4 increases in hepatic labora-
tory abnormalities were observed more frequently in HBV/
HCV-coinfected patients than in patients who were not coin-
fected (Table 4). The majority of patients had increased indirect
bilirubin above the normal limit. In HBV/HCV-coinfected patients,
3/54 patients (5.6%) in the rilpivirine group and 1/66 patients
(1.5%) in the efavirenz group had a treatment-emergent indirect
bilirubin level above normal. In patients without HBV/HCV
coinfection, the proportions were 32/631 patients (5.1%)
versus 2/603 (0.3%), respectively.
Discussion
Analysis of the pooled 48 week data from the ECHO and THRIVE
trials showed that rilpivirine and efavirenz have comparable effi-
cacy and hepatic safety profiles in antiretroviral treatment-naive
patients coinfected with HIV-1 and HBV or HCV. Response rates
were similar for rilpivirine and efavirenz within the HBV/
HCV-coinfected and non-coinfected groups. Overall, the response
rate was lower in HBV/HCV-coinfected patients than in patients
Table 3. Frequency of treatment-emergent hepatic AEs by HBV and/or HCV coinfection status (N¼1368)a
Treatment-emergent hepatic AEs, n (%)
HIV patients with HBV/HCV coinfection HIV patients without HBV/HCV coinfection
25 mg of RPV once
daily, N¼54
600 mg of EFV once
daily, N¼66
25 mg of RPV once daily,
N¼632
600 mg of EFV once daily,
N¼616
Any hepatic AE 15 (27.8) 17 (25.8) 23 (3.6) 28 (4.5)
Hepatobiliary disordersb 3 (5.6) 7 (10.6) 6 (0.9) 9 (1.5)
cholelithiasis — — 4 (0.6) 1 (0.2)
cytolytic hepatitis — 1 (1.5) — —
abnormal hepatic function — 3 (4.5) — —
hepatic steatosis — 2 (3.0) — —
hepatitis 1 (1.9) — — 1 (0.2)
acute hepatitis — — — 1 (0.2)
hepatomegaly 1 (1.9) 1 (1.5) 1 (0.2) 3 (0.5)
hyperbilirubinaemia (total) 1 (1.9) — 1 (0.2) 1 (0.2)
hypertransaminasaemia — — 1 (0.2) 2 (0.3)
Incident cases of HBV or HCVc 3 (5.6) 5 (7.6) — —
HBV 1 (1.9) 1 (1.5) — —
HCV 2 (3.7) 4 (6.1) — —
Hepatic laboratory abnormalities reported
as an AEd
9 (16.7) 8 (12.1) 19 (3.0) 21 (3.4)
abnormal ALT — — 1 (0.2) —
increased ALT 6 (11.1) 7 (10.6) 7 (1.1) 12 (1.9)
increased AST 7 (13.0) 5 (7.6) 9 (1.4) 14 (2.3)
increased blood alkaline phosphatase — — — 3 (0.5)
increased blood bilirubin — — 4 (0.6) —
increased unconjugated blood bilirubin — — 1 (0.2) —
increased hepatic enzyme 1 (1.9) 1 (1.5) — 1 (0.2)
abnormal liver function test — — 2 (0.3) 1 (0.2)
increased transaminases 1 (1.9) — 1 (0.2) 4 (0.6)
RPV, rilpivirine; EFV, efavirenz.
aPatient numbers are higher than for the efficacy analyses because the safety analyses were performed using all available data, including beyond
week 48.
bSelection of preferred terms from the System Organ Class, as defined by MedDRA.
cPatients who seroconverted for HBV/HCV during the study were also included in the subgroup of HIV/HBV- and/or HIV/HCV-coinfected patients.
dSelection of preferred terms reported under the System Organ Class of investigations, not hepatobiliary disorders.
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who were not coinfected, with the difference being statistically
significant for rilpivirine. The lower overall response rate in coin-
fected than in non-coinfected patients in the rilpivirine group
was due to more discontinuations for reasons other than AEs
(12.2% discontinuations for coinfected versus 4.0% for non-
coinfected patients, respectively). For efavirenz, the main
reason for the lower response rate in coinfected than in non-
coinfected patients was a higher discontinuation rate due to
AEs (9.5% versus 6.6% for non-coinfected patients). Virological
failure rates were similar within each treatment group, regard-
less of the HIV/HBV and/or HIV/HCV coinfection status (10.2%
in coinfected patients versus 8.9% in non-coinfected patients
for rilpivirine, and 4.8% and 5.0%, respectively, for efavirenz).
In general, both rilpivirine and efavirenz were well tolerated,
with no hepatic safety differences observed. Rilpivirine was,
however, associated with a lower incidence of grade 2–4
increases in liver function test enzymes compared with efavirenz.
While hyperbilirubinaemia (grade 1–3) was more frequent in the
rilpivirine group compared with the efavirenz group, the majority
of patients had an increased indirect bilirubin above the normal
limit, which is not indicative of hepatic toxicity. This could be due
to an interaction with a transporter or due to conjugation, but
additional in vitro experiments would be required to explore
this further. There have been no signs of haemolysis in pre-
clinical or clinical studies. There were no grade 4 cases of hyper-
bilirubinaemia in either group. Consistent with observations from
previous studies,13 – 19,32,40 hepatic AEs occurred more frequently
in HBV- and/or HCV-coinfected patients than in those patients
who were not coinfected (26.7% versus 4.1%, respectively).
Our results suggest that the liver safety profile of rilpivirine is
similar to that of efavirenz.
Hepatotoxicity can lead to morbidity, mortality and the dis-
continuation of antiretroviral therapy in HIV patients, and those
who are coinfected with HBV or HCV are more vulnerable.40 Al-
though varying degrees of drug-related liver injury have been
associated with almost every antiretroviral regimen, previous
reports suggest that NNRTIs tend to cause a slight increase in
the cumulative incidence of hepatotoxicity with prolonged use,
especially in HBV/HCV-coinfected patients.21,40,46 However, this
analysis showed that liver-related AEs were uncommon with ril-
pivirine or efavirenz over ≥48 weeks of treatment. Moreover,
most of the hepatic AEs reported were laboratory abnormalities,
generally asymptomatic grade 1 or 2 increases in transaminase
levels, rather than clinical hepatic AEs. These findings are similar
to those of other studies on the safety of NNRTIs.32,47
The current pooled analysis of two trials has several limitations.
The individual trials were not designed to compare rilpivirine with
efavirenz in coinfected patients. In addition, patients entering the
trials were highly selected, e.g. those with clinically significant
hepatic impairment or ALT and/or AST levels five times above the
upper limit of normal were excluded. As such, this subpopulation
was restricted to mild-to-moderately hepatically impaired
Table 4. Frequency of grade 2–4 treatment-emergent hepatic laboratory abnormalities occurring in ≥2% of patients per treatment group by HIV/
HBV and/or HIV/HCV coinfection status (N¼1368)a
Laboratory parameter, n (%)
HIV patients with HBV/HCV coinfection HIV patients without HBV/HCV coinfection
25 mg of RPV once daily,
N¼54
600 mg of EFV once daily,
N¼66
25 mg of RPV once daily,
N¼631b
600 mg of EFV once daily,
N¼604b
Increased alkaline phosphatase
all grades 4 (7.4) 13 (19.7) 16 (2.5) 75 (12.4)
grade 2–3c 0 2 (3.0) 1 (0.2) 6 (1.0)
Increased ALT
all grades 27 (50.0) 28 (42.4) 114 (18.1) 161 (26.7)
grade 2–4 18 (33.3) 19 (28.8) 17 (2.7) 47 (7.8)
Increased ASTd
all grades 22 (40.7) 24 (36.4) 94 (14.9) 146 (24.7)
grade 2–4 11 (20.4) 12 (18.2) 22 (3.5) 48 (7.9)
Hyperbilirubinaemia (total)e
all grades 7 (13.0) 1 (1.5) 50 (7.9) 4 (0.7)
grade 2–3c 4 (7.4) 1 (1.5) 17 (2.7) 2 (0.3)
RPV, rilpivirine; EFV, efavirenz.
aPatient numbers are higher than for the efficacy analyses because the safety analyses were performed using all available data, including beyond
week 48; patients who seroconverted for HBV/HCV during the study were also included in the subgroup of HIV/HBV- and/or HIV/HCV-coinfected
patients.
bNumber of patients with data.
cNo grade 4 laboratory abnormality observed.
dData available for 603 patients in the efavirenz non-coinfected group.
eThe majority of patients had increased indirect bilirubin above the normal limit.
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patients, and thus the proportion of HBV/HCV-coinfected patients
(8.4%) was different (smaller) compared with the incidence of
coinfection previously reported in Western Europe and the USA
(HCV coinfection: 25%–30%; HBV coinfection: 6%–14%).1
However, treatment comparison within the study remains valid.
Also, this exclusion criterion meant the safety of rilpivirine or efa-
virenz in patients with more advanced liver disease at baseline
was not explored. The small numbers preclude: separate analyses
of the HBV- and HCV-coinfected patients; further study of the
effect on response and safety of other baseline risk factors; or
further study of the background N(t)RTIs that have anti-HBV activ-
ity (tenofovir, lamivudine and emtricitabine). Lastly, it is beyond
the scope of this analysis to determine the reasons for the differ-
ences in the virological response and tolerability profile between
HBV/HCV-coinfected patients and non-coinfected patients, e.g.
whether or not they are due to an intrinsic effect of the NNRTIs.
The results of the analysis suggest that hepatic AEs are more
common and the response rates lower in HBV/HCV-coinfected
patients than in patients with HIV who are not coinfected,
when treated with rilpivirine or efavirenz. Rilpivirine demon-
strated an efficacy and hepatic safety profile similar to that of
efavirenz in both coinfected and non-coinfected individuals.
Standard clinical monitoring is considered adequate when HBV/
HCV-coinfected patients receive a HAART regimen that includes
rilpivirine. Finally, clinical practice will also be guided by the ex-
tensive drug interactions study programme being conducted
with rilpivirine, particularly in the light of the known drug interac-
tions between some current ARVs and certain HCV therapies.
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